massively parallel sequencing

FTC Moves to Block Illumina's $8B Grail Acquisition

Twist Bioscience, Biotia Nab FDA EUA for Hybridization-Based NGS SARS-CoV-2 Assay

Illumina, Geneseeq Technology to Collaborate on IVD Cancer Testing Kits in China

Adaptive Biotechnologies Q4 Revenues Rise 25 Percent

Fulgent Genetics, BioIQ Partner on NGS-Based SARS-CoV-2 Variant Detection

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Clear Labs, Integrated DNA Technologies Expand Partnership to Include COVID-19 Testing

Illumina, Harvard Pilgrim Health Care Ink Risk-Sharing Deal for Whole-Genome Sequencing

Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

China NMPA Approves Illumina NextSeq 550Dx Sequencer for Genetic Testing and Diagnosis

Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test

Adaptive Biotechnologies Q3 Revenues Grow 1 Percent

Invitae, Pacific Biosciences Collaborate on NGS-Based Pediatric Epilepsy Testing

Fulgent Genetics Revenues More Than Double in Q2, Driven by COVID-19 Testing

Blue Shield of California to Cover Rady Children's Rapid Whole-Genome Sequencing Test

MGI Receives CE Mark, Regulatory Clearance in Asia-Pacific Countries for Several Sequencers